Bioclassifier, NanoString to 'Decentralize' Breast Cancer Test as ARUP Preps qPCR Version
December 09, 2010
Bioclassifier, NanoString to 'Decentralize' Breast Cancer Test as ARUP Preps qPCR Version
Bioclassifier has licensed to NanoString the rights to develop in vitro diagnostic and research products based on the so-called PAM50 gene signature and NanoString's nCounter platform. Meantime, ARUP Laboratories will next month launch a laboratory-developed qPCR test based on the signature.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Dx Focus: Clinical and Regulatory PCR and Nucleic Acid Testing News
January 20, 2011 / PCR Insider - ARUP Labs Develops Modified Allele-Specific qPCR Assay for BRAF V600E Mutation
January 24, 2013 / PCR Insider - Personalized Medicine Highlights from San Antonio Breast Cancer Symposium 2012
December 12, 2012 / Pharmacogenomics Reporter - GMU Phosphoproteomic Studies Offer Potential Clinical Insights on Breast, Colorectal Cancers
October 12, 2012 / ProteoMonitor - MDx/CDx Focus: NanoString Kicks off Second PAM50 Validation Study; MDxHealth Launches ConfirmMDx
May 16, 2012 / Pharmacogenomics Reporter